Related Experiment Video
Updated: Sep 28, 2026

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
[Brugada's syndrome: experience in Cuba in 2001]
Francisco Dorticós Balea1, Margarita Dorantes Sánchez, Jorge Luis Arbaiza Simón
1Servicio de Arritmias y Estimulación Cardíaca, Instituto de Cardiología y Cirugía Cardiovascular Ciudad de La Habana, Cuba. marccard@infomed.sld.cu
Insights
Brugada syndrome, a genetic heart condition, was studied in 14 Cuban patients. Early diagnosis and implantable cardioverter-defibrillators are key for managing life-threatening arrhythmias and preventing sudden cardiac death.
Area of Science:
- Cardiology
- Electrophysiology
- Genetics
Context:
- Brugada syndrome is a primary electrical disorder causing sudden cardiac death in individuals with structurally normal hearts.
- It presents with characteristic ECG abnormalities like ST segment elevation and pseudo right bundle branch block.
- The syndrome predisposes individuals to life-threatening ventricular arrhythmias.
Purpose:
- To characterize patients diagnosed with Brugada syndrome in Cuba between 1995 and 2001.
- To evaluate diagnostic tools and treatment strategies for Brugada syndrome in this cohort.
Summary:
- Fourteen patients (13 male, 1 female, mean age 42.8) were studied, with 7 symptomatic and 7 asymptomatic.
- Pharmacological testing with sodium channel blockers proved highly effective (100% positive).
- Programmed ventricular stimulation induced arrhythmias in 5 patients (3 symptomatic, 2 asymptomatic).
- Implantable cardioverter-defibrillators were used for all symptomatic patients and inducible asymptomatic cases.
- A single recurrence of ventricular arrhythmia was noted, with rare use of antiarrhythmic drugs.
Impact:
- Highlights the diagnostic utility of clinical history, ECG, and pharmacological challenge in Brugada syndrome.
- Emphasizes the implantable cardioverter-defibrillator as the primary treatment for preventing sudden cardiac death.
- Suggests that even masked or transient ECG findings warrant consideration for Brugada syndrome diagnosis.
Abstract:
The Brugada syndrome is the most frequent electrical cause of sudden death in patients with structurally normal heart. It is characterized by ST segment elevation in V1-V3 leads, pseudo right bundle branch block and proneness for episodes of life-threatening ventricular cardiac arrhythmias. The aim of this study was to characterize patients with Brugada syndrome identified in Cuba between 1995 and 2001. Fourteen patients with these electrical signs (13 male and 1 female, mean age 42.8) were studied. Seven of them were symptomatic and seven were not. The pharmacological test with sodium channel blockers was very useful (it was positive for all the patients). HV interval was normal. Programmed ventricular stimulation was performed. Ventricular arrhythmia was inducible in 3 symptomatic patients and 2 asymptomatic. All the symptomatic patients and those asymptomatic in whom ventricular arrhythmia was inducible received automatic defibrillators. One clinical recurrence of ventricular arrhythmias was observed. Antiarrhythmic drugs were only used rarely. Clinical history and electrocardiographic tracings were very important to diagnose this syndrome. There were light, transient or masked electrical signs. The treatment of choice is the implantable cardioverter-defibrillator.
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Amebiasis
Huntington Disease l: Introduction
American Trypanosomiasis
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Giardiasis

